- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.04. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.04. | Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist | 84 | PR Newswire | PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and... ► Artikel lesen | |
| 03.04. | Harmony Biosciences Initiates Global Phase 3 Registrational Trial (tempo Study) Of Pitolisant In Patients With Prader-willi Syndrome | 70 | PR Newswire | PLYMOUTH MEETING, Pa., April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate... ► Artikel lesen | |
| 28.03. | Evaluating Harmony Biosciences: Insights From 8 Financial Analysts | 1 | Benzinga.com | ||
| 19.03. | Harmony Biosciences exec sells over $383k in stock | 1 | Investing.com | ||
| 28.02. | Harmony Biosciences Holdings, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 23.02. | Earnings call: Harmony Biosciences reports 2023 growth driven by WAKIX | 1 | Investing.com | ||
| 22.02. | Harmony Biosciences Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.02. | Raymond James lifts Harmony Biosciences target on steady net patient adds | 2 | Investing.com | ||
| 22.02. | Analyst Ratings For Harmony Biosciences | 1 | Benzinga.com | ||
| 22.02. | Harmony Biosciences Holdings, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 22.02. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.02. | Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | 146 | GlobeNewswire (Europe) | WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| 22.02. | Harmony Biosciences Non-GAAP EPS of $0.73 misses by $0.18, revenue of $168.4M in-line | 1 | Seeking Alpha | ||
| 21.02. | Harmony Biosciences Q4 2023 Earnings Preview | 1 | Seeking Alpha | ||
| 21.02. | Harmony Biosciences Sinks on FDA Nod | - | Baystreet.ca | ||
| 21.02. | Harmony Biosciences Receives FDA Priority Review For Wakix | 1 | RTTNews | ||
| 20.02. | Harmony Biosciences Receives FDA's Orphan Drug Designation For Pitolisant In Prader-Willi Syndrome | 1 | RTTNews | ||
| 20.02. | Harmony Biosciences Receives U.S. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-willi Syndrome | 179 | PR Newswire | PLYMOUTH MEETING, Pa., Feb. 20, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation... ► Artikel lesen | |
| 08.01. | Harmony Biosciences says Q4 preliminary net product revenue was about $168M | 3 | Seeking Alpha |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,595 | -2,45 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 53,25 | +0,47 % | CRISPR Therapeutics' Options Frenzy: What You Need to Know | ||
| MAINZ BIOMED | 0,898 | +4,06 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
| DEFENCE THERAPEUTICS | 0,950 | +0,64 % | KI im Gesundheitswesen mit evotec, Defence Therapeutics, Bayer: Revolutionäre Fortschritte und medizinische Durchbrüche | Im Gesundheitswesen nimmt Künstliche Intelligenz (KI) immer mehr an Fahrt auf. KI-basierte Systeme können medizinische Datenbanken nutzen, um in der Forschung kostbare Zeit zu sparen, die es Unternehmen... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,925 | 0,00 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 35,480 | -0,17 % | 9 Analysts Have This To Say About Halozyme Therapeutics | ||
| BEAM THERAPEUTICS | 24,310 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,975 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA | Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer
Overall survival results from the randomized HR+/HER2- metastatic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,400 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| ARGENX | 343,00 | +1,81 % | The Analyst Verdict: argenx In The Eyes Of 12 Experts | ||
| ARDELYX | 6,084 | +0,53 % | Ardelyx, Inc. Reports Employment Inducement Grants | WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,310 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,754 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,240 | 0,00 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,680 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen |
Das Unternehmen HARMONY BIOSCIENCES HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 29,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
